{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"The primary safety outcome is indicated by the number of participants who died at or before Day 100 after transplant for any reason other than relapse of disease (Leukemia, Lymphoma, Hodgkin's disease, Hematologic Neoplasms, Multiple Myeloma, Renal Cell Carcinoma).","groups":[{"description":"Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic \\[related or unrelated\\] Hematopoietic SCT.\n\nPentostatin: 4 mg/m2/24 hour IV continuously over 72 hours on days -8 to -6. Alemtuzumab: 20 mg per dose IV over 8 hours on days -5 to -1. Patients then received infusion of related or unrelated donor peripheral blood progenitor cells on day 0. Patients also receive cyclosporine IV continuously beginning on day -2, continuing (IV or orally) until day 100, followed by a taper.","id":"OG000","title":"Preparative Regimen of Pentostatin and Alemtuzumab"}],"paramType":"NUMBER","populationDescription":"All participants who received at least 1 day of treatment.","reportingStatus":"POSTED","timeFrame":"Day 100 after transplant","title":"Non-relapse Mortality at or Before Day 100","type":"PRIMARY","unitOfMeasure":"Participants"}